This asset seems geared towards a partner deal - the ones with progressive milestones that runs into the $1+ billion + yearly royalties if the asset makes it to market.
my 2 cents is that PYC should post this presentation on their LinkedIn while they are still BIO to help with awareness.
Someone like Roche with more infrastructure/$ could help partner/accelerate this to market for the benefit of patients
Ann: Phelan-McDermid Syndrome & CNS platform presentation, page-3
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.3¢ | $190.9K | 1.808M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 541363 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 226352 | 5 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
10.5¢ |
Change
0.000 ( 4.55 %) |
||||
| Open | High | Low | Volume | ||
| 11.0¢ | 11.0¢ | 10.3¢ | 1733037 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| PYC (ASX) Chart |